RANIBIZUMAB
( DrugBank: Ranibizumab / KEGG DRUG: Ranibizumab )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
| 166 | Pseudoxanthoma elasticum | 4 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 1 |
| 301 | Macular dystrophy | 1 |
34. Neurofibromatosis
Clinical trials : 179 / Drugs : 259 - (DrugBank : 84) / Drug target genes : 90 - Drug target pathways : 211
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
166. Pseudoxanthoma elasticum
Clinical trials : 21 / Drugs : 30 - (DrugBank : 6) / Drug target genes : 5 - Drug target pathways : 27
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
227. Osler disease
Clinical trials : 68 / Drugs : 93 - (DrugBank : 22) / Drug target genes : 25 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
301. Macular dystrophy
Clinical trials : 69 / Drugs : 66 - (DrugBank : 15) / Drug target genes : 10 - Drug target pathways : 80
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|